Art. -Nr.: HY-142870

ZY-444

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

ZY-444 is an anti-cancer agent, targeting pyruvate carboxylase (PC). ZY-444 suppresses the Wnt/β-catenin/Snail signaling pathway by blocking nuclear translocation of β-catenin. ZY-444 selectively inhibits proliferation, migration, and invasion and induces apoptosis in cancer cells. ZY-444 exhibits potent anti-tumor in cancer mouse models. ZY-444 can be used for the study of breast cancer, lung cancer (NSCLC), prostate cancer and iodine-refractory thyroid cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.51%
CAS. Nr.: 1802650-31-2
Formel: C₂₆H₂₈N₄OS
Molecular Weight:444.59

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ZY-444 Chemical Structure

CAS. Nr.: 1802650-31-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle Wnt Isoform-spezifische Produkte anzeigen :

In Vitro

ZY-444 (0-10 μM, 48 h) inhibits BCA cell lines (MDA-MB-231 and 4T1) and (PCa cells DU145 and PC3) proliferation, migration, and invasion^[1][2].
ZY-444 (0-20 μM, 24 h) significantly induces apoptosis in BCA cells (MDA-MB-231, MCF7, 4T1)^[1].
ZY-444 (2-18 μM, 5 h) dose-dependently decreases basal respiration, spare respiratory capacity, and ATP production in BCA cells (MDA-MB-231)^[1].
ZY-444 (0-10 μM, 24 h) downregulates total expression of key Wnt/β-catenin/Snail pathway proteins in MDA-MB-231 cells, prevents nuclear translocation of β-catenin, and similar effects are observed in PC-silenced MDA-MB-231 cells^[1].
ZY-444 (24-72 h) halves the proliferation ability of TPC-1 and KTC-1 cells, with IC₅₀ values of 3.82 μM (48 h) and 3.34 μM (72 h) for TPC-1 cells, and 3.79 μM (48 h) and 3.69 μM (72 h) for KTC-1 cells^[3].
ZY-444 significantly inhibits the activation of the MAPK/ERK signaling pathway in TPC-1 and KTC-1 cells, reducing the expression levels of ERK1/2 and p-ERK1/2^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

MDA-MB-231, MCF7, and 4T1cells
Concentration:

0, 5, 6, 8, 10, 15, 20 μM
Incubation Time:

24 h
Result:

Induced apoptosis in BCA cells (MDA-MB-231, MCF7).
Increased apoptotic cells.
Upregulated expression of apoptotic biomarkers (cleaved caspase-3, cleaved PARP).
Downregulated anti-apoptotic biomarker (Bcl-2).

Cell Invasion Assay^[1]

Cell Line:

MDA-MB-231 cells
Concentration:

0, 6, 8, 10 μM
Incubation Time:

24 h
Result:

Downregulated expression of mesenchymal markers (Snail1, Snail2, Vimentin, N-cadherin) associated with epithelial-mesenchymal transition (EMT).

Western Blot Analysis^[1]

Cell Line:

MDA-MB-231, MCF7, and 4T1cells
Concentration:

MDA-MB-231 cells
Incubation Time:

24 h
Result:

Downregulated total expression of β-catenin, c-Myc, and Cyclin D1 in MDA-MB-231 cells.
Prevented nuclear translocation of β-catenin (increased cytosolic β-catenin).

In Vivo

ZY-444 (2.5-5 mg/kg, i.p., daily or every 2 days, 26 days) exhibits potent anti-tumor and anti-metastatic efficacy in orthotopic 4T1 and MDA-MB-231 breast cancer mouse model^[1].
ZY-444 (2.5-5 mg/kg, i.p., daily, 24 days) demonstrates excellent anti-prostate cancer efficacy in DU145 xenograft model^[2].
ZY-444 (daily, 12 days) exhibits inhibitory effect on the growth of xenograft tumors derived from TPC-1 and KTC-1 PTC cells in 4-week-old female BALB/c nude mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4T1 or MDA-MB-231 breast cancer cells were orthotopically implanted into female mice^[1]
Dosage:

2.5, 5 mg/kg
Administration:

i.p., daily or every 2 days, 26 days
Result:

Achieved tumor growth inhibition.
Showed no significant changes in body weight.
Upregulated apoptotic biomarkers and downregulated mesenchymal biomarkers in primary tumors.

Animal Model:

DU145 cells (5 × 10⁷) were subcutaneously implanted into the right flanks of 6-8-week-old male NOD-scid mice^[2]
Dosage:

2.5, 5 mg/kg
Administration:

i.p., daily, 24 days
Result:

Achieved tumor growth inhibition.
Showed no significant changes in body weight.
Reduced the Ki67 expression.
Upregulated the expression of TNFAIP3 and IKBα, while downregulated the expression of RIPK1, IKKα, p-IKBα, NF-κB, and p-p65.

Chemical Information

CAS. Nr. 1802650-31-2
Appearance Solid
Molecular Weight 444.59
Formel C₂₆H₂₈N₄OS
Color Light yellow to yellow
SMILES

CC(C)CNC1=NC=CC(NCC2=CC=C(C3=CC=C(OCC4=CC=CC=C4)C=C3)S2)=N1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Commun Biol

Pyruvate carboxylase promotes SREBP1a-mediated lipid synthesis in epithelial ovarian cancer. [Abstract]

2026 May 14. PMID: 42129486

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (224.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2493 mL

11.2463 mL

22.4926 mL

5 mM

0.4499 mL

2.2493 mL

4.4985 mL

10 mM

0.2249 mL

1.1246 mL

2.2493 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lin Q, et al. Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression. Adv Sci (Weinh). 2020 Mar 12;7(9):1903483. [Content Brief]

[2]. Han MT, et al. ZY-444 inhibits the growth and metastasis of prostate cancer by targeting TNFAIP3 through TNF signaling pathway. Am J Cancer Res. 2023 Apr 15;13(4):1533-1546. [Content Brief]

[3]. Liu Y, et al. Pyruvate carboxylase promotes malignant transformation of papillary thyroid carcinoma and reduces iodine uptake. Cell Death Discov. 2022 Oct 20;8(1):423. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2493 mL	11.2463 mL	22.4926 mL	56.2316 mL
	5 mM	0.4499 mL	2.2493 mL	4.4985 mL	11.2463 mL
	10 mM	0.2249 mL	1.1246 mL	2.2493 mL	5.6232 mL
	15 mM	0.1500 mL	0.7498 mL	1.4995 mL	3.7488 mL
	20 mM	0.1125 mL	0.5623 mL	1.1246 mL	2.8116 mL
	25 mM	0.0900 mL	0.4499 mL	0.8997 mL	2.2493 mL
	30 mM	0.0750 mL	0.3749 mL	0.7498 mL	1.8744 mL
	40 mM	0.0562 mL	0.2812 mL	0.5623 mL	1.4058 mL
	50 mM	0.0450 mL	0.2249 mL	0.4499 mL	1.1246 mL
	60 mM	0.0375 mL	0.1874 mL	0.3749 mL	0.9372 mL
	80 mM	0.0281 mL	0.1406 mL	0.2812 mL	0.7029 mL
	100 mM	0.0225 mL	0.1125 mL	0.2249 mL	0.5623 mL

Keywords

ZY-444

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ZY-444

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Antihypertensive Compound Library

TCA Cycle Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) ZY-444

Alle ERK Isoform-spezifische Produkte anzeigen

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

ZY-444 Related Classifications

HY-142870 Related Classifications